It is the cache of http://mcpharmacol.com/index.php/Journals/article/view/61. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Integrins and Oncogenes: Partners in Crime | Puigvert | Molecular and Cellular Pharmacology

Molecular and Cellular Pharmacology, Vol 1, No 5 (2009)

Font Size:  Small  Medium  Large
Cover Image

Integrins and Oncogenes: Partners in Crime

Jordi Carreras Puigvert, Louise von Stechow, Bob van de Water, Erik HJ Danen

Abstract


Metastatic spread and acquired or intrinsic resistance to existing therapies form the two major obstacles in cancer treatment. Accumulating evidence indicates that cancer growth, metastasis, and the response to therapy are strongly affected by integrin-mediated interactions with the extracellular matrix (ECM) in the tumor microenvironment. Indeed, altered expression levels of various integrins has been associated with poor differentiation, increased metastasis, and decreased overall and recurrence-free survival after radio- or chemotherapy in different types of cancer. Recent evidence indicates that the role of specific integrins in cancer progression and treatment response depends on the spectrum of oncogenic mutations present in cancer cells. In this PharmSight, we discuss several examples of such cross talk between integrins and oncogenes that may point to new avenues for cancer therapy.


Full Text: PDF


LumiText Publishing, P.O. Box 774, Ellicott City, MD 21041 

Copyright © 2008 LumiText Publishing. All rights reserved.